CN108323763A - 一种富硒组合物及制剂的应用 - Google Patents
一种富硒组合物及制剂的应用 Download PDFInfo
- Publication number
- CN108323763A CN108323763A CN201810106103.4A CN201810106103A CN108323763A CN 108323763 A CN108323763 A CN 108323763A CN 201810106103 A CN201810106103 A CN 201810106103A CN 108323763 A CN108323763 A CN 108323763A
- Authority
- CN
- China
- Prior art keywords
- group
- selenium
- preparation
- sample
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011669 selenium Substances 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 229910001385 heavy metal Inorganic materials 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 7
- 231100000614 poison Toxicity 0.000 claims abstract description 6
- 239000002574 poison Substances 0.000 claims abstract description 6
- 235000005911 diet Nutrition 0.000 claims abstract description 3
- 230000037213 diet Effects 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims abstract description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract description 13
- 229910052793 cadmium Inorganic materials 0.000 abstract description 13
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 abstract description 13
- 229910052731 fluorine Inorganic materials 0.000 abstract description 13
- 239000011737 fluorine Substances 0.000 abstract description 13
- 241001465754 Metazoa Species 0.000 abstract description 5
- 230000008485 antagonism Effects 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052753 mercury Inorganic materials 0.000 abstract description 4
- 231100000572 poisoning Toxicity 0.000 abstract description 4
- 230000000607 poisoning effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 210000001503 joint Anatomy 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 238000011109 contamination Methods 0.000 description 20
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 17
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000011775 sodium fluoride Substances 0.000 description 6
- 235000013024 sodium fluoride Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 tetramethyl azo azoles salt Chemical class 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MPDDQFGQTCEFIX-UHFFFAOYSA-N [F].[Ca] Chemical compound [F].[Ca] MPDDQFGQTCEFIX-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- DGJPPCSCQOIWCP-UHFFFAOYSA-N cadmium mercury Chemical class [Cd].[Hg] DGJPPCSCQOIWCP-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000002803 fossil fuel Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及一种富硒组合物及制剂的应用。具体是作为制备解重金属毒的药品、保健食品、功能性普通食品、特殊医学配方食品、特殊膳食食品的应用，属于大健康应用技术领域。本发明选用与镉联合作用对LLC‑PKl细胞脂质过氧化的影响、对氟中毒动物生化指标的影响、对铅镉汞联合损害的拮抗作用几项技术验证，发现该富硒组合物及制剂具有明显的解重金属毒效果，因此可在解重金属毒方面进行应用。
Description
技术领域
本发明涉及一种富硒组合物及制剂的应用。具体是作为制备解重金属毒的药品、保健食品、功能性普通食品、特殊医学配方食品、特殊膳食食品的应用，属于大健康应用技术领域。
技术背景
一方面，重金属污染作为一个日渐被人们关注的环境问题，其产生的原因及影响都备受社会关注。其中，矿山开采，金属冶炼，重金属加工，化工废水，化石燃料的大规模应用，以及施用的农药化肥和生活垃圾等人为污染源，已经严重污染了生态环境，而且威胁了人类及其他生物的生存与安全。
另一方面，生物体过量摄入重金属能够使蛋白质结构发生不可逆的改变，让机体内催化酶丧失催化化学反应功能、细胞膜表面的载体不能运入营养物质和排出代谢废物、肌球蛋白和肌动蛋白无法完成肌肉收缩，从而影响组织细胞功能，让体内细胞无法获得营养、排除废物、产生能量、细胞结构崩溃和功能丧失，进而影响机体健康，给人类带来极大的危害。随着人类工业的发展，研究和探索一款能够对重金属有很好的解毒作用的产品就显得尤为重要且迫在眉睫。
申请号为201810104156.2的发明专利，公开了一种富硒组合物及制剂，其制备方法和应用。作为该专利的发明人，在实施该专利的过程中不断的探索和研究，开辟了富硒组合物及制剂的新用途。
发明内容
本发明的目的在于开辟申请号为201810104156.2，一种富硒组合物及制剂，其制备方法和新用途。
本发明的目的是采用以下技术方案来实现的。
本发明选用与镉联合作用对LLC-PKl细胞脂质过氧化的影响、对氟中毒动物生化指标的影响、对铅镉汞联合损害的拮抗作用几项技术验证，发现该富硒组合物及制剂具有明显的解重金属毒效果，因此可应用于解重金属毒。
具体实施方式：
下面通过具体实施例对本发明作进一步说明，但不以任何方式对本发明限制，基于本发明教导所作的任何变化或替换，均属本发明保护范围。
实施例1：组合物料的制备
富硒酵母：直接购置保健品营养素补充剂原料，经检测硒含量(以Se计)为0.07％。
维生素C：直接购置食品级原料，经检测维生素C含量(以L-抗坏血酸计)为99.79％。
乳糖、预胶化淀粉、硬脂酸镁：直接购置食品级原料。
实施例2：富硒乳化物制备
富硒乳化物按昆明朗盛生物科技有限公司《一种富硒组合物及制剂，其制备方法和应用》(申请号：201810104156.2)制备。经检测富硒乳化物中硒含量为0.018％。
实施例3：组合物制备
取实施例2制备的富硒乳化物，按昆明朗盛生物科技有限公司《一种富硒组合物及制剂，其制备方法和应用》(申请号：201810104156.2)制备组合物，经检测组合物中硒含量为0.0062％，维生素C含量为19.96％。
为了更进一步对本发明技术效果进行说明，本发明选取实施例3所制备的组合物作为试验样品，编号为④。选取实施例1准备的富硒酵母、维生素C、实施例2制备的富硒乳化物、编号依次为①、②、③。开展解重金属毒的比较试验，结果如下：
1.与镉联合作用对LLC-PKl细胞脂质过氧化的影响
试验动物及器材：氯化镉(CdCl2)(纯度≥98.O％)，胰蛋白酶、四甲基偶氮唑盐、二甲基亚砜；RPMI 1640培养、小牛血清，SOD、GSH-Px、MDA试剂盒购自南京建成生物工程研究所。主要仪器有：酶标仪、DU-650紫外可见分光光度计。
造模、分组及实验：LLC-PKl细胞培养。培养液选用RPMI 1640，加10％小牛血清和双抗(青霉素和链霉素各100U/ml)，于恒温细胞培养箱(37℃，5％C02)中培养，待细胞贴壁生长约90％传代，每周传代2-3次。
实验分为空白对照组和实验组。实验组又分为①、②、③、④组。每组各设6个平行样。
⑴.四甲基偶氮唑盐(MTT)比色法
取传代生长达90％的细胞用0.25％的胰酶消化制成单细胞悬液，并调整细胞浓度，180μl/孔，使接种于96孔培养板的细胞数约1×104/孔，并设置无细胞的空白孔。放置于37℃、5％C02培养箱中12h,更换无血清RPMI 1640培养液12h后，加入氯化镉或同时加入①、②、③、④并对细胞分别染毒12h，再加5mg/ml MTT，20μl/孔，培养4h后小心弃去孔内液，每孔加DMSO 150μl，充分振摇15min后用酶标仪于570nm处测各孔吸光度值(A)。各剂量组取平均值，根据实验公式，计算细胞的相对存活率：
细胞相对存活率(％)＝实验组A/对照组A×100％。
⑵.SOD、GSH-Px、MDA的检测
氯化镉分别与①、②、③、④联合作用对LLC-PKl细胞染毒12h后，取培养上清液用于SOD、GSH-Px、MDA的测定。黄嘌呤氧化酶法测定SOD活力，以催化GSH反应速度表示GSH-Px的活力，TBA法测定MDA含量。结果见表1、2、3。
表1镉对LLC-PK1细胞增殖的影响(12h)
| CdCl2浓度(μmol/L) | 0 | 20 | 40 | 60 | 80 | 100 |
| Cell相对存活率(％) | 100 | 64 | 22 | 10 | 9 | 8 |
由表1可以看出，20μmol/L CdCl2已呈现明显的毒性效应，细胞的相对存活率(64％)明显降低。随着CdCl2浓度的增加，其毒性作用逐渐增大。
表2各组与镉联合作用对LLC-PK1细胞活力的影响(12h)
从表2可以看出，样品①、②、③、④与30μmol/L CdCl2联合作用的细胞存活率明显高于与30μmol/L CdCl2单独作用组，样品④相较于样品①、②、③细胞存活率显著提高(p<0.01)，显示出良好的改善作用。
表3与镉联合作用LLC-PK1细胞12h培养液S0D、GSH-Px活力与MDA含量变化
从表3看出：样品④组较CdCl2组及样品①～③组相比，MDA含量有显著性下降，表明样品④组对镉引起的脂质过氧化具有显著的拮抗作用，CuZn-SOD、Mn-SOD和GSH-Px均有显著性升高，这可能由于脂质过氧化产物MDA等有害物质可使细胞膜受到损伤，细胞膜通透性增加而使细胞内CuZn-SOD、Mn-SOD、GSH-Px逸出到细胞外液中，使细胞外液中抗氧化酶活性随之上升；也可能是细胞对脂质过氧化的应激性反应而使抗氧化酶活性增加的结果。
实验结论
样品④(即实施例3所制备的组合物)与镉联合作用不仅使细胞相对存活率显著性升高，而且可对镉引起的脂质过氧化具有显著的拮抗作用。
2.对氟中毒动物生化指标的影响
考察指标确定：为了更进一步对本发明组合物技术效果进行说明，选取编号为①②③④作为试验样品，同时设置正常组和染毒组进行对照，以排除造模干扰与误差。开展对照组、实验组对大鼠腹主动脉取血，并测血清中Ca、P、ALP(碱性磷酸酶)含量，取右侧股骨测骨胶原和骨钙含量,胶原按羟脯氨酸含量换算。取左侧股骨测骨氟含量,留取24小时尿,测尿氟含量。
实验动物及器材：体重110～140g的Wistar大白鼠、偏食饲料：配方为:玉米面89％、黄豆面10％,精盐1％、碳酸钙1g/kg，200mg/L的氟化钠蒸馏水。
给样剂量：本发明所述组合物(试验样品④)60kg成年人给样剂量确定为1g/天，据此折算每天大鼠给样剂量为104.2mg/kg(其中含富硒酵母9.4mg，含维生素C 20.8mg)。依据等剂量给样可比原则确定样品③每天给样剂量为35.6mg/kg(其中含富硒酵母9.4mg)，依据等剂量给样可比原则，结合国家药典或相关行业标准推荐日最高给样剂量确定样品②每天给样剂量为52.6mg/kg，样品①每天给样剂量为14.9mg/kg。
造模分组及实验：实验用体重110～140g的Wistar大白鼠60只，分为6个组，每组10只，雌雄各半。正常组(喂给大鼠偏食饲料+生理盐水)；染毒组(偏食饲料+氟化钠蒸馏水)；实验组：样品①组(偏食饲料+氟化钠蒸馏水+样品①)；样品②组(偏食饲料+氟化钠蒸馏水+样品②)；样品③组(偏食饲料+氟化钠蒸馏水+样品③)；样品④组(偏食饲料+氟化钠蒸馏水+样品④)。饲养两个月后，用乙醚麻醉，腹主动脉取血，并测血清中Ca、P、ALP(碱性磷酸酶)含量，取右侧股骨测骨胶原和骨钙含量,胶原按羟脯氨酸含量换算。取左侧股骨测骨氟含量,留取24小时尿,测尿氟含量。实验结果详见表4、表5。
表4：各组大鼠中血清中Ca、P、ALP(碱性磷酸酶)含量
表5：各组大鼠中骨胶原、骨钙、尿氟、骨氟的含量
从表4和表5看出：与正常组相比，染毒组血清Ca含量显著降低(p＜0.01)，ALP(P＜0.01)、尿氟(P＜0.01)、骨氟(P＜0.01)值均显著增高，说明染毒大鼠模型成功建立。
样品④组较染毒组及样品①②③组Ca含量显著增加，ALP值显著降低、尿氟值显著增高，本发明所述富硒组合物(样品④)能显著增加血清中的Ca含量，显著降低血清中ALP的含量，并且增加尿液中氟的排泄量。说明本发明所述组合物(样品④)可以对于氟致血清中钙含量降低、ALP增加及骨质破坏进行有效改善。
3.对铅镉汞联合损害的拮抗作用
考察指标确定：为了更进一步对本发明组合物技术效果进行说明，选取编号为①②③④作为试验样品，同时设置正常组和染毒组进行对照，以排除造模干扰与误差。开展对照样品、试验样品对小鼠血清中丙氨酸转氨酶(ALT)和碱性磷酸酶(ALP)活力、全血中谷胱甘肽过氧化物酶GSH-Px活力和骨髓嗜多染红细胞微核率试验。
实验动物及器材：昆明种小白鼠，体重18～25g，雌雄各半，测血清中丙氨酸转氨酶(ALT)和碱性磷酸酶(ALP)活力，测全血中谷胱甘肽过氧化物酶GSH-Px活力测定试剂盒以及配制染毒剂，取小鼠股骨，按GBl5193.5.94骨髓微核试验检测骨髓嗜多染红细胞微核率。
给药剂量：染毒剂量：乙酸铅12.8mg/kg(以铅计7mg/kg)，CdCl2mg/kg(以镉计1mg/kg)，HgCl2 0.95mg/kg(以汞计0.7mg/kg)①富硒酵母组(21.5mg/kg+染毒)；②维生素C组(75.8mg/kg+染毒)；③富硒乳化物组(51.3mg/kg+染毒)含富硒酵母9.4mg；④组合物组(150mg/kg+染毒)含富硒酵母9.4mg，维生素C 20.8mg。
造模、分组及实验：取72只小鼠随机分成12组。每组6只，雌雄各半。设为正常组、染毒组、实验①②③④组。分2批进行，第1批6组动物，每日上午染毒，下午进行给药。连续染毒3天。第12天处死。第2批6组动物比第1批动物晚4天进行，当天上午染毒，次日上午进行给药。连续染毒3天。第12天处死。动物在灌胃后给予正常饮水和饲料，且正常组给予同等剂量的生理盐水。实验结束时，摘除小鼠眼球法采血，分别置入肝素抗凝管获得全血和非抗凝管获得血清，于4℃冰箱保存，用于酶活力测定。取小鼠右肢股骨，进行骨髓细胞微核试验。详见结果见表6。
表6：血清中ALT和ALP值(U/L)全血中GSH-Px值及鼠骨髓嗜多染红细胞微核率
实验结论：
从表6可以看出：与正常组相比，染毒组血清ALT数值(P<0.01)、全血GSH-Px酶活性均显著降低(P<0.01)，骨髓嗜多染红细胞微核率显著升高(P<0.01)，说明染毒组小鼠模型成功建立。
正常组、染毒组及样品①②③④对于ALP值的差异无显著性，表明急性染毒对ALP值没有显著性。样品④组较染毒组及样品①②③组ALT(P<0.01)数值明显升高，GSH-Px(P<0.01)数值有提升，骨髓嗜多染红细胞微核率(P<0.01)显著降低，说明本发明所述组合物(样品④)能有效提升染毒条件下血清中丙氨酸转氨酶(ALT)(P<0.01)和全血中谷胱甘肽过氧化物酶GSH-Px(P<0.01)活力，且降低骨髓嗜多染红细胞微核率(P<0.01)，能有效改进铅镉汞联合对小鼠的重金属染毒作用。
Claims (1)
1.一种富硒组合物及制剂的应用，其特征在于该富硒组合物作为制备解重金属毒的药品、保健食品、功能性普通食品、特殊医学配方食品、特殊膳食食品的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810106103.4A CN108323763B (zh) | 2018-02-02 | 2018-02-02 | 一种富硒组合物及制剂的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810106103.4A CN108323763B (zh) | 2018-02-02 | 2018-02-02 | 一种富硒组合物及制剂的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108323763A true CN108323763A (zh) | 2018-07-27 |
| CN108323763B CN108323763B (zh) | 2021-05-28 |
Family
ID=62927743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810106103.4A Active CN108323763B (zh) | 2018-02-02 | 2018-02-02 | 一种富硒组合物及制剂的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108323763B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846514A (zh) * | 2005-04-14 | 2006-10-18 | 中国人民解放军总后勤部军需装备研究所 | 硒蛋白奶片 |
| CN1911062A (zh) * | 2006-08-21 | 2007-02-14 | 吴永尧 | 植物源天然富硒肽及其制备方法和用途 |
| CN103667409A (zh) * | 2014-01-06 | 2014-03-26 | 南京财经大学 | 一种缓解铅毒性的富硒米肽酶解制备方法 |
| CN106036883A (zh) * | 2016-06-01 | 2016-10-26 | 南京财经大学 | 一种含硒蛋白和灵芝成分的解毒复合片及其制备方法 |
| CN106343569A (zh) * | 2016-08-31 | 2017-01-25 | 广西梧州市港圣堂保健食品有限公司 | 一种促进铅排泄的富硒食品及其制备方法 |
-
2018
- 2018-02-02 CN CN201810106103.4A patent/CN108323763B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846514A (zh) * | 2005-04-14 | 2006-10-18 | 中国人民解放军总后勤部军需装备研究所 | 硒蛋白奶片 |
| CN1911062A (zh) * | 2006-08-21 | 2007-02-14 | 吴永尧 | 植物源天然富硒肽及其制备方法和用途 |
| CN103667409A (zh) * | 2014-01-06 | 2014-03-26 | 南京财经大学 | 一种缓解铅毒性的富硒米肽酶解制备方法 |
| CN106036883A (zh) * | 2016-06-01 | 2016-10-26 | 南京财经大学 | 一种含硒蛋白和灵芝成分的解毒复合片及其制备方法 |
| CN106343569A (zh) * | 2016-08-31 | 2017-01-25 | 广西梧州市港圣堂保健食品有限公司 | 一种促进铅排泄的富硒食品及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108323763B (zh) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Cyclopiazonic acid biosynthesis of Aspergillus flavus and Aspergillus oryzae | |
| Chang et al. | Suppression of aflatoxin biosynthesis in Aspergillus flavus by 2-phenylethanol is associated with stimulated growth and decreased degradation of branched-chain amino acids | |
| Mendoza-Arroyo et al. | Inorganic phosphate solubilization by a novel isolated bacterial strain Enterobacter sp. ITCB-09 and its application potential as biofertilizer | |
| Zielinski et al. | Biological activity of hydrophilic extract of Chlorella vulgaris grown on post-fermentation leachate from a biogas plant supplied with stillage and maize silage | |
| CN107365827A (zh) | 一种将单磺酸四氮唑盐用于检测细胞活力的用途及方法 | |
| Avni et al. | Olive mill waste enhances α-glucan content in the edible mushroom Pleurotus eryngii | |
| Polikovsky et al. | Engineering bacteria-seaweed symbioses for modulating the photosynthate content of Ulva (Chlorophyta): Significant for the feedstock of bioethanol production | |
| CN110218756B (zh) | 一种具有抗衰作用的富硒鲟鱼骨肽提取方法及产品 | |
| Oszust et al. | Trichoderma-based biopreparation with prebiotics supplementation for the naturalization of raspberry plant rhizosphere | |
| Pagnussatt et al. | Fusarium graminearum growth inhibition mechanism using phenolic compounds from Spirulina sp | |
| Li et al. | Effects of the fungal endophyte Epichloë festucae var. lolii on growth and physiological responses of perennial ryegrass cv. fairway to combined drought and pathogen stresses | |
| de Evan et al. | Evaluation of Brassica vegetables as potential feed for ruminants | |
| DK200200408A (da) | Selengærprodukt, fremgangsmåde til fremstilling af et selengærprodukt samt anvendelse af produktet til fremstilling af en fødevare, et kosttilskud, eller et lægemiddel | |
| CN107384811A (zh) | 一种白囊耙齿菌及其应用 | |
| Dzhavakhiya et al. | Effect of various compounds blocking the colony pigmentation on the aflatoxin B1 production by Aspergillus flavus | |
| Thiviya et al. | Production of single-cell protein from fruit peel wastes using palmyrah toddy yeast | |
| Olsen et al. | Outdoor cultivation of a novel isolate of the microalgae Scenedesmus sp. and the evaluation of its potential as a novel protein crop | |
| De Saeger et al. | Report from the 5th International symposium on mycotoxins and toxigenic Moulds: challenges and perspectives (MYTOX) held in Ghent, Belgium, May 2016 | |
| Dmitrović et al. | Dairy and wine industry effluents as alternative media for the production of Bacillus-based biocontrol agents | |
| Borràs-Vallverdú et al. | Influence of agronomic factors on mycotoxin contamination in maize and changes during a 10-day harvest-till-drying simulation period: a different perspective | |
| Ammar et al. | Nutritive Value of Ajuga iva as a pastoral plant for ruminants: plant phytochemicals and in vitro gas production and digestibility | |
| CN108323763A (zh) | 一种富硒组合物及制剂的应用 | |
| Krupodorova et al. | Strain-specific features of Pleurotus ostreatus growth in vitro and some of its biological activities | |
| Jang et al. | Antidiabetic, anticholesterol, and antioxidant activity of Gryllus bimaculatus fermented by Bacillus and Lactobacillus strains | |
| CN101974460A (zh) | 一种海洋来源Bacillus barbaricus SCSIO 02429以及用它制备鱿鱼小肽的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |